Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Benzodiazepine Withdrawal Symptom Questionnaire.

Literature DB >> 1971833

The Benzodiazepine Withdrawal Symptom Questionnaire.

Abstract

A self-report questionnaire is described which records the main symptoms experienced during withdrawal from benzodiazepines in pharmacologically dependent patients. The questionnaire consists of 20 items; evidence is given that these are reasonably independent and are sensitive in detecting withdrawal symptoms from a study of 68 patients undergoing slow withdrawal from benzodiazepines.

Entities: Chemical Species

Mesh：

Substances：

Year: 1990 PMID： 1971833 DOI： 10.1016/0165-0327(90)90009-w

Source DB: PubMed Journal: J Affect Disord ISSN： 0165-0327 Impact factor: 4.839

Keyword Cloud
Cited

31 in total

1. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.

Authors: W Joseph Herring; Kathleen M Connor; Ellen Snyder; Duane B Snavely; Ying Zhang; Jill Hutzelmann; Deborah Matzura-Wolfe; Ruth M Benca; Andrew D Krystal; James K Walsh; Christopher Lines; Thomas Roth; David Michelson
Journal: J Clin Sleep Med Date: 2016-09-15 Impact factor: 4.062

2. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.

Authors: Sonia Ancoli-Israel; Andrew D Krystal; W Vaughn McCall; Kendyl Schaefer; Amy Wilson; Raymond Claus; Robert Rubens; Thomas Roth
Journal: Sleep Date: 2010-02 Impact factor: 5.849

3. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.

Authors: Timothy A Roehrs; S Randall; E Harris; R Maan; T Roth
Journal: J Psychopharmacol Date: 2011-10-16 Impact factor: 4.153

4. Psychological treatment of hypnotic-dependent insomnia in a primarily older adult sample.

Authors: Kenneth L Lichstein; Sidney D Nau; Nancy M Wilson; R Neal Aguillard; Kristin W Lester; Andrew J Bush; Christina S McCrae
Journal: Behav Res Ther Date: 2013-09-26

5. Gradual withdrawal from benzodiazepines in residents of homes for the elderly: experience and suggestions for future research.

Authors: H Habraken; K Soenen; L Blondeel; J Van Elsen; J Bourda; E Coppens; M Willeput
Journal: Eur J Clin Pharmacol Date: 1997 Impact factor: 2.953

6. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial.

Authors: Ritva Lähteenmäki; Juha Puustinen; Tero Vahlberg; Alan Lyles; Pertti J Neuvonen; Markku Partinen; Ismo Räihä; Sirkka-Liisa Kivelä
Journal: Br J Clin Pharmacol Date: 2014-06 Impact factor: 4.335

The Benzodiazepine Withdrawal Symptom Questionnaire.

1. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.

2. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.

3. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.

4. Psychological treatment of hypnotic-dependent insomnia in a primarily older adult sample.

5. Gradual withdrawal from benzodiazepines in residents of homes for the elderly: experience and suggestions for future research.

6. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial.

7. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.

Review 8. Benzodiazepine dependence. Avoidance and withdrawal.

9. Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study.

10. Indiplon in the management of insomnia.